Pioneering enterprise in modernizing oriental medicine
From a small production team in the railway industry established in 1972, Traphaco was born with the mission of producing medicine to serve the North - South railway line, throughout the war years.
In the period of innovation, with strategic vision and pioneering spirit, Traphaco is a pioneer enterprise in modernizing Vietnamese oriental medicine, opening a different direction - combining traditional medical knowledge with modern technology.
Since 2009, Traphaco has implemented the GreenPlan Project - Research and sustainable development of Vietnamese medicinal resources, forming a "4-house" model (State - Scientists - Farmers - Enterprises), closely linking production and community livelihoods.
Up to now, the company has developed 11 medicinal herb areas meeting GACP-WHO standards in Lao Cai, Ninh Binh (former Nam Dinh), Phu Tho, Dak Lak (former Phu Yen ), ... with more than 880 households participating in planting and harvesting medicinal herbs meeting standards, thousands of hectares of medicinal herbs are controlled according to GACP-WHO guidelines.
Representative of Traphaco Board of Directors received Vietnam record certificate
Traphaco is one of the first enterprises in Vietnam to build a large-scale chain of GACP-WHO standard growing areas, becoming a model for the Vietnamese pharmaceutical industry in terms of quality from the source - transparency throughout the process.
According to the World Health Organization's GACP-WHO standards, all processes from seed selection, cultivation, irrigation, harvesting, preservation to transportation of medicinal herbs are strictly controlled to ensure that the input medicinal herbs are safe, clean, free of chemical residues and have the highest active ingredient content.
Each growing area is not only a source of high-quality raw materials but also a sustainable poverty reduction model, helping people have a stable income many times higher than rice and corn cultivation, contributing to land preservation, forest preservation and conservation of native ecosystems.
Entering the integration phase, Traphaco has identified a parallel development strategy: High-quality Oriental Medicine - High-quality Western Medicine. Familiar brands such as Boganic, Hoat Huyet Duong Nao, Tottri, Cebraton continue to affirm their top position in the market, while Boganic Premium and Cebraton Premium open a new path for modern Oriental medicine products.
Traphaco is confident with the strong competitiveness of its two strategic product lines.
High quality medicine, reasonable cost
In the field of modern medicine, Traphaco has implemented strategic cooperation with Daewoong Group, one of the three leading pharmaceutical companies in Korea, to receive technology transfer and improve the capacity to produce high-quality drugs. From 2021 to now, the project has entered phase 3 with more than 40 products transferred from Daewoong Group, out of a total of 8 phases and 70 key products of the program.
Traphaco implements strategic cooperation with Daewoong Group in transferring technology to produce high-quality Western medicine
At the same time, Traphaco actively promotes research and development of bioequivalent (BE) drugs and first generic drugs to meet the increasing treatment needs of Vietnamese patients. This cooperation not only shortens the product research and development process, but also improves technical capacity, opening up opportunities to export "Made in Vietnam" drugs.
Bioequivalent drugs (BE) are Traphaco's spearhead in the high-quality Western medicine segment.
In 2025, Traphaco will carry out a dual movement: restructuring the distribution system and comprehensive digital transformation. The company has streamlined its branch model, established a national order center and a specialized logistics company, and applied artificial intelligence (AI) to core activities: medicinal material testing, accounting, supply chain, customer care and marketing.
The AI system for managing the quality of raw materials allows tracing each batch of medicinal herbs from the growing area to the finished product, improving control capacity and operational efficiency.
Throughout the journey of development and brand affirmation, the company has continuously maintained the title of "National Brand", been honored in the Top 10 Sustainable Enterprises CSI, Top 50 Best Listed Companies in Vietnam (Forbes), Excellent and Sustainable Enterprises in Asia, and Top 10 Golden Stars of Vietnam for many years. Key products such as Boganic, Hoat Huyet Duong Nao, Tottri, Cebraton continuously hold the top position in the market share of Vietnamese Oriental medicine.
With a foundation of more than half a century of accumulation, Traphaco has identified its strategy for the next phase as a "technology pharmaceutical enterprise" model, based on three pillars: R&D - Technology transfer - Digital supply chain. The company is implementing the EU-GMP standard factory project, expanding research on AI applications in medicinal material testing and quality management, aiming at international standards on production, safety and sustainability.
"Traphaco 53 years for Vietnamese health" is not only a word of gratitude but also a commitment to millions of consumers who have trusted and accompanied Traphaco.
In the first 9 months of 2025, Traphaco's revenue increased by 8.5% and profit increased by 8% compared to the same period in 2024. Two strategic product groups: high-quality oriental medicine and high-quality Western medicine grew by 65% and 55% respectively, contributing 13% of total revenue, becoming the key driving force of the company.
Traphaco aims to have 17 bioequivalent drug products by the end of 2025, helping Vietnamese patients access high-quality drugs at reasonable costs.
Source: https://thanhnien.vn/traphaco-53-nam-vi-suc-khoe-viet-185251127164511917.htm
Comment (0)